Effect of Fluvastatin Sodium (XU62-320), a New Inhibitor of 3-hydroxy-3-methylglutaryl Coenzyme A Reductase, on the Induction of Low-density Lipoprotein Receptor in HepG2 Cells
Overview
Biophysics
Authors
Affiliations
The effect of fluvastatin sodium (XU62-320), a new type of inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A, on the induction of LDL receptor in the human liver-derived cell line HepG2 was investigated. Fluvastatin sodium produced marked inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity and induction of LDL receptor on HepG2 cells at a concentration of 0.1-1.0 microM. These results suggest that fluvastatin sodium has potential for use as a strong plasma cholesterol-lowering drug.
Maenaka A, Kenta I, Ota A, Miwa Y, Ohashi W, Horimi K FEBS Open Bio. 2020; 10(5):927-936.
PMID: 32237049 PMC: 7193171. DOI: 10.1002/2211-5463.12854.
Bader T, Korba B Antiviral Res. 2010; 86(3):241-5.
PMID: 20211652 PMC: 2869246. DOI: 10.1016/j.antiviral.2010.02.325.
Antiproliferative effect of fluvastatin and thiazolidinedione in mesangial cells of diabetic rats.
Okada M, Yanagida H, Kuwajima H, Takemura T Pediatr Nephrol. 2003; 19(1):26-32.
PMID: 14634862 DOI: 10.1007/s00467-003-1306-y.
Clinical pharmacokinetics of fluvastatin.
Scripture C, Pieper J Clin Pharmacokinet. 2001; 40(4):263-81.
PMID: 11368292 DOI: 10.2165/00003088-200140040-00003.
Fluvastatin: a review of its pharmacology and use in the management of hypercholesterolaemia.
Plosker G, Wagstaff A Drugs. 1996; 51(3):433-59.
PMID: 8882381 DOI: 10.2165/00003495-199651030-00011.